Research programme: CETP inhibitors - Bristol-Myers SquibbAlternative Names: BMS-795311
Latest Information Update: 16 Dec 2011
At a glance
- Originator Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cardiovascular disorders